Jefferies Financial Group Initiates Coverage on Aligos Therapeutics (NASDAQ:ALGS)

Equities researchers at Jefferies Financial Group began coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a report released on Monday, Zacks reports. The brokerage set a “strong-buy” rating on the stock.

Several other research analysts have also recently issued reports on ALGS. Weiss Ratings cut shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. HC Wainwright reaffirmed a “buy” rating on shares of Aligos Therapeutics in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Aligos Therapeutics Trading Down 2.9%

Shares of NASDAQ ALGS opened at $3.95 on Monday. Aligos Therapeutics has a twelve month low of $3.95 and a twelve month high of $13.69. The stock has a 50 day moving average of $5.25 and a two-hundred day moving average of $6.15.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Friday, November 6th. The company reported ($2.09) earnings per share for the quarter, beating the consensus estimate of ($2.28) by $0.19. The business had revenue of $2.87 million during the quarter, compared to the consensus estimate of $4.85 million. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%. On average, equities research analysts forecast that Aligos Therapeutics will post -6.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE grew its holdings in Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after purchasing an additional 216,646 shares in the last quarter. SummitTX Capital L.P. increased its holdings in shares of Aligos Therapeutics by 6.7% in the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after acquiring an additional 9,375 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Aligos Therapeutics by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock worth $746,000 after buying an additional 15,006 shares during the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.